We recently reported, using MCF-7 non-invasive breast cancer cells, selected to homogenously respond to IL-1β (6D cells), that this cytokine induces a signaling pathway that contributes to the activation of β-catenin, overexpression of several genes involved in the epithelial–mesenchymal transition (EMT), and chemoresistance [3,4,5,6]. This evidence concerns the gene IL1B and breast carcinoma.